Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 4, 2014, Pages 423-431

  Van Driest, S L ^a   Shi, Y ^b   Bowton, E ^b   Schildcrout, J ^b   Peterson, J ^b,c   Pulley, J ^b   Denny, J ^b,c   Roden, D ^b,d  

^a MONROE CARELL JR CHILDREN S HOSPITAL AT VANDERBILT   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MERCAPTOPURINE; PRASUGREL; SIMVASTATIN; TACROLIMUS; WARFARIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; GENE FREQUENCY; GENETIC SCREENING; GENETIC VARIABILITY; GENOTYPE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHARMACOGENOMICS; PRIORITY JOURNAL;

AFRICAN AMERICANS; AGED; FEMALE; GENE FREQUENCY; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS;

EID: 84896637856     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.229     Document Type: Article

References (37)

1. Collins, F.S., Green, E.D., Guttmacher, A.E & Guyer, M.S.; US National Human Genome Research Institute. A vision for the future of genomics research. Nature 422, 835-847 (2003.
2. Crews, K.R. et al.; Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 91, 321-326 (2012.
3. Johnson, J.A. et al.; Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011.
4. Scott, S.A. et al.; Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90, 328-332 (2011.
5. Scott, S.A. et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94, 317-323 (2013.
6. Relling, M.V. et al.; Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 89, 387-391 (2011.
7. Relling, M.V. et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin. Pharmacol. Ther. 93, 324-325 (2013.
8. Wilke, R.A. et al.; Clinical Pharmacogenomics Implementation Consortium (CPIC). The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92, 112-117 (2012.
9. Pulley, J.M. et al. Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92, 87-95 (2012.
10. Mega, J.L et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306, 2221-2228 (2011.
11. Ogg, M.S., Brennan, P., Meade, T. & Humphries, S.E. CYP2C9 3 allelic variant and bleeding complications. Lancet 354, 1124 (1999.
12. Ablin, J., Cabili, S., Lagziel, A. & Peretz, H. Warfarin therapy in a patient homozygous for the CYP2C9 3 allele. Isr. Med. Assoc. J. 4, 139-141 (2002.
13. Steward, D.J et al. Genetic association between sensitivity to warfarin and expression of CYP2C9 3. Pharmacogenetics 7, 361-367 (1997.
14. Hicks, J.K. et al.; Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93, 402-408 (2013.
15. Martin, M.A., Klein, T.E., Dong, B.J., Pirmohamed, M., Haas, D.W. & Kroetz, D.L.; Clinical Pharmacogenetics Implementation Consortium Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin. Pharmacol. Ther. 91, 734-738 (2012.
16. Hershfield, M.S. et al. Clinical pharmacogenetics implementation consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin. Pharmacol. Ther. 93, 153-158 (2013.
17. Caudle, K.E. et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin. Pharmacol. Ther. 94, 640-645 (2013.
18. McDonagh, E.M., Thorn, C.F., Bautista, J.M., Youngster, I., Altman, R.B. & Klein, T.E. PharmGKB summary: Very important pharmacogene information for G6PD. Pharmacogenet. Genomics 22, 219-228 (2012.
19. Muir, A.J. et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-A-based regimens. Clin. Pharmacol. Ther. (2013); e-pub ahead of print 4 October 2013.
20. Liu, X., Cheng, D., Kuang, Q., Liu, G & Xu W. Association of UGT1A1 28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: A meta-Analysis in Caucasians. Pharmacogenomics J (2013); e-pub ahead of print 26 March 2013.
21. Ramsey, B.W. et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365, 1663-1672 (2011.
22. Leckband, S.G. et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin. Pharmacol. Ther. 94, 324-328 (2013.
23. Hippisley-Cox, J & Coupland, C. Individualising the risks of statins in men and women in England and Wales: Population-based cohort study. Heart 96, 939-947 (2010.
24. Chung, J.Y. et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 78, 342-350 (2005.
25. Lee, E. et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78, 330-341 (2005.
26. Ramirez, A.H et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 13, 407-418 (2012.
27. Kumar, R. et al. Genetic ancestry in lung-function predictions. N. Engl. J. Med. 363, 321-330 (2010.
28. Schildcrout, J.S. et al. Optimizing drug outcomes through pharmacogenetics: A case for preemptive genotyping. Clin. Pharmacol. Ther. 92, 235-242 (2012.
29. Xu, H., Stenner, S.P., Doan, S., Johnson, K.B., Waitman, L.R. & Denny, J.C. MedEx: A medication information extraction system for clinical narratives. J. Am. Med. Inform. Assoc. 17, 19-24 (2010.
30. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
31. Chinevere, T.D., Murray, C.K., Grant, E. Jr, Johnson, G.A., Duelm, F. & Hospenthal, D.R. Prevalence of glucose-6-phosphate dehydrogenase deficiency in U.S. Army personnel. Mil. Med. 171, 905-907 (2006.
32. Ge, Det al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009.
33. Girard, H. et al. UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. Mutat. Res. 644, 56-63 (2008.
34. Mattison, L.K., Fourie, J., Desmond, R.A., Modak, A., Saif, M.W. & Diasio, R.B. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin. Cancer Res. 12, 5491-5495 (2006.
35. Monaghan, K.G., Bluhm, D., Phillips, M. & Feldman, G.L. Preconception and prenatal cystic fibrosis carrier screening of African Americans reveals unanticipated frequencies for specific mutations. Genet. Med. 6, 141-144 (2004.
36. Saif, M.W Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU-And capecitabinerelated toxicity using full sequencing of DPYD. Cancer Genomics Proteomics 10, 89-92 (2013.
37. Wei, X et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51, 391-400 (1998.